Market Cap 661.97M
Revenue (ttm) 0.00
Net Income (ttm) -95.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.25
Volume 1,108,300
Avg Vol 1,365,766
Day's Range N/A - N/A
Shares Out 172.84M
Stochastic %K 52%
Beta 0.56
Analysts Strong Sell
Price Target $8.81

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 512 614 1848
Address:
1717 Langhorne Newtown Road, Suite 300, Langhorne, United States
STOCKALERTIST
STOCKALERTIST Sep. 11 at 1:42 PM
$NVAX sharply up and $SVRA is squeezing
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 11 at 1:40 PM
$SVRA expect this to cross $3.95 today ad over $4.00 the the major squeeze will start. stock up!!!!
1 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 11 at 1:34 PM
$SVRA could squeeze!!
0 · Reply
JarvisFlow
JarvisFlow Sep. 9 at 1:00 PM
Guggenheim has updated their rating for Savara ( $SVRA ) to Buy with a price target of 11.
0 · Reply
art62
art62 Sep. 8 at 7:07 PM
$SVRA Prior post credit to A. Tsai Jefferies---> eaning 12-15 dollars
1 · Reply
art62
art62 Sep. 8 at 7:02 PM
$SVRA ".... (1) The completion of CMC work by early Q4 with drug supplier Fujifilm (+5-10% stock move) should trigger add'l catalysts, such as (2) a BLA acceptance in Q1:26 (+5-15% move), (3) AdCom in mid-2026 (perhaps +15-35%), and (4) PDUFA as early as Aug 2026..Mgmt's latest market research confirms the diagnosed US population could actually be 50% larger, prompting us to raise our peak sales estimate to $500M (up from prior $400M), which could still be conservative. Net-net, $500M sales x high 4-5x multiple (biosimilar competition is unlikely) = $2.0-2.5B valuation (up from $800M+ cap)."
0 · Reply
IN0V8
IN0V8 Sep. 8 at 3:01 PM
$SVRA Opportunity to watch Jefferies raises target price to $10.5 from $8.5
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 12:30 PM
Oppenheimer updates rating for Savara ( $SVRA ) to Outperform, target set at 6 → 8.
0 · Reply
TeeMan123
TeeMan123 Sep. 8 at 12:34 AM
$SVRA Jefferies increases price target to $10.50 .. increasing peak sales expectations to $500MM
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 5 at 7:25 PM
$SOUN and $SVRA is squeezing!!!
0 · Reply
Latest News on SVRA
Savara Announces New Employment Inducement Grant

Jul 18, 2025, 4:05 PM EDT - 7 weeks ago

Savara Announces New Employment Inducement Grant


Savara: Make-It-Or-Break-It Molbreevi BLA Filing

Apr 21, 2025, 11:16 AM EDT - 5 months ago

Savara: Make-It-Or-Break-It Molbreevi BLA Filing


Savara Announces Participation in Upcoming Healthcare Conferences

Nov 13, 2024, 8:05 AM EST - 10 months ago

Savara Announces Participation in Upcoming Healthcare Conferences


STOCKALERTIST
STOCKALERTIST Sep. 11 at 1:42 PM
$NVAX sharply up and $SVRA is squeezing
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 11 at 1:40 PM
$SVRA expect this to cross $3.95 today ad over $4.00 the the major squeeze will start. stock up!!!!
1 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 11 at 1:34 PM
$SVRA could squeeze!!
0 · Reply
JarvisFlow
JarvisFlow Sep. 9 at 1:00 PM
Guggenheim has updated their rating for Savara ( $SVRA ) to Buy with a price target of 11.
0 · Reply
art62
art62 Sep. 8 at 7:07 PM
$SVRA Prior post credit to A. Tsai Jefferies---> eaning 12-15 dollars
1 · Reply
art62
art62 Sep. 8 at 7:02 PM
$SVRA ".... (1) The completion of CMC work by early Q4 with drug supplier Fujifilm (+5-10% stock move) should trigger add'l catalysts, such as (2) a BLA acceptance in Q1:26 (+5-15% move), (3) AdCom in mid-2026 (perhaps +15-35%), and (4) PDUFA as early as Aug 2026..Mgmt's latest market research confirms the diagnosed US population could actually be 50% larger, prompting us to raise our peak sales estimate to $500M (up from prior $400M), which could still be conservative. Net-net, $500M sales x high 4-5x multiple (biosimilar competition is unlikely) = $2.0-2.5B valuation (up from $800M+ cap)."
0 · Reply
IN0V8
IN0V8 Sep. 8 at 3:01 PM
$SVRA Opportunity to watch Jefferies raises target price to $10.5 from $8.5
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 12:30 PM
Oppenheimer updates rating for Savara ( $SVRA ) to Outperform, target set at 6 → 8.
0 · Reply
TeeMan123
TeeMan123 Sep. 8 at 12:34 AM
$SVRA Jefferies increases price target to $10.50 .. increasing peak sales expectations to $500MM
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 5 at 7:25 PM
$SOUN and $SVRA is squeezing!!!
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 5 at 4:04 PM
$NVAX is curling and $SVRA is squeezing
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 5 at 4:03 PM
$AMD is curling and $SVRA is squeezing
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 5 at 4:02 PM
$BBAI is curling and $SVRA is squeezing
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 5 at 3:52 PM
$SVRA SQUEEZING GET THE WORD OUT!!! BUT JUMP IN BEFORE
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 5 at 3:51 PM
$SVRA Short squeeze is coming in !!
0 · Reply
STOCKALERTIST
STOCKALERTIST Sep. 5 at 11:01 AM
$SVRA a short squeezee in the making??
0 · Reply
IN0V8
IN0V8 Sep. 4 at 3:50 PM
$SVRA Watch / Opportunity H.C. Wainwright raises target price to $8 from $5
0 · Reply
JarvisFlow
JarvisFlow Sep. 3 at 2:36 PM
HC Wainwright & Co. has updated their rating for Savara ( $SVRA ) to Buy with a price target of 8.
0 · Reply
50bps
50bps Sep. 3 at 2:03 PM
$SVRA 👀
0 · Reply
Zeffanator2
Zeffanator2 Sep. 3 at 12:08 AM
$SVRA A little after hours never hurts. She’s definitely do for a break out.
0 · Reply
Spacemonkey1
Spacemonkey1 Sep. 2 at 3:51 PM
$SVRA not sure why this wouldn’t go up considering they just found 50% more patients.
1 · Reply
ZAPP_ZAPPER
ZAPP_ZAPPER Aug. 31 at 2:21 AM
$BINI But did you win ? $ZAPP $SVRA $FFI
1 · Reply